Clinical Trial Update: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating AK104, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Recurrent Cervical Cancer, Metastatic Cervical Cancer | Phase 2 | Status: COMPLETED